ALB 127158A

Drug Profile

ALB 127158A

Alternative Names: ALB-127158(a)

Latest Information Update: 05 Oct 2011

Price : $50

At a glance

  • Originator AMRI
  • Class Obesity therapies; Small molecules
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 03 Oct 2011 Discontinued - Phase-I for Obesity in United Kingdom (PO)
  • 03 Oct 2011 Final pharmacokinetics, adverse events and efficacy data from two phase I trials in healthy volunteers and patients with Obesity released by AMRI
  • 01 Jun 2011 Topline adverse events and preliminary efficacy data from a phase I trial in volunteers released by AMRI
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top